| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Dialysis | 65 | 2025 | 949 | 9.960 |
Why?
|
| Kidney Failure, Chronic | 56 | 2025 | 937 | 8.520 |
Why?
|
| Renal Insufficiency, Chronic | 49 | 2026 | 846 | 6.670 |
Why?
|
| Glomerular Filtration Rate | 42 | 2026 | 568 | 5.670 |
Why?
|
| Kidney | 13 | 2024 | 1280 | 2.860 |
Why?
|
| Cardiovascular Diseases | 29 | 2026 | 2101 | 2.320 |
Why?
|
| Kidney Function Tests | 8 | 2023 | 135 | 2.210 |
Why?
|
| Urea | 5 | 2025 | 219 | 1.790 |
Why?
|
| Hypertension | 11 | 2022 | 1347 | 1.620 |
Why?
|
| Death, Sudden, Cardiac | 5 | 2021 | 271 | 1.620 |
Why?
|
| Cystatin C | 10 | 2022 | 73 | 1.610 |
Why?
|
| Quality of Life | 10 | 2024 | 2074 | 1.410 |
Why?
|
| Biomarkers | 31 | 2025 | 3386 | 1.350 |
Why?
|
| Point-of-Care Systems | 3 | 2019 | 212 | 1.310 |
Why?
|
| Lipocalins | 6 | 2017 | 31 | 1.270 |
Why?
|
| Intramolecular Oxidoreductases | 6 | 2017 | 41 | 1.260 |
Why?
|
| Antihypertensive Agents | 8 | 2020 | 415 | 1.240 |
Why?
|
| Middle Aged | 88 | 2026 | 28415 | 1.220 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2021 | 62 | 1.200 |
Why?
|
| Iohexol | 3 | 2024 | 19 | 1.160 |
Why?
|
| Indican | 6 | 2019 | 8 | 1.140 |
Why?
|
| Arrhythmias, Cardiac | 5 | 2021 | 484 | 1.090 |
Why?
|
| Risk Assessment | 18 | 2026 | 3678 | 1.090 |
Why?
|
| Kidney Diseases | 4 | 2018 | 471 | 1.090 |
Why?
|
| Humans | 143 | 2026 | 130555 | 1.090 |
Why?
|
| Creatinine | 13 | 2024 | 396 | 1.070 |
Why?
|
| Nephrology | 2 | 2019 | 159 | 0.980 |
Why?
|
| Diabetes Mellitus, Type 2 | 9 | 2026 | 1444 | 0.960 |
Why?
|
| Male | 97 | 2026 | 64534 | 0.910 |
Why?
|
| Aged | 61 | 2026 | 20899 | 0.910 |
Why?
|
| Cresols | 4 | 2017 | 10 | 0.890 |
Why?
|
| Practice Guidelines as Topic | 5 | 2026 | 1288 | 0.880 |
Why?
|
| Risk Factors | 44 | 2026 | 10967 | 0.880 |
Why?
|
| Disease Progression | 12 | 2026 | 2193 | 0.870 |
Why?
|
| Female | 99 | 2026 | 70425 | 0.860 |
Why?
|
| Prospective Studies | 29 | 2022 | 6438 | 0.850 |
Why?
|
| Metabolomics | 5 | 2024 | 501 | 0.820 |
Why?
|
| Troponin I | 2 | 2016 | 122 | 0.820 |
Why?
|
| Heart Failure | 8 | 2026 | 2326 | 0.810 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2021 | 325 | 0.780 |
Why?
|
| Sulfuric Acid Esters | 3 | 2017 | 15 | 0.750 |
Why?
|
| Blood Pressure | 8 | 2017 | 1342 | 0.730 |
Why?
|
| Peptide Fragments | 3 | 2021 | 688 | 0.720 |
Why?
|
| Cohort Studies | 27 | 2025 | 5049 | 0.690 |
Why?
|
| Diabetic Nephropathies | 5 | 2026 | 115 | 0.680 |
Why?
|
| Clinical Competence | 2 | 2019 | 1060 | 0.670 |
Why?
|
| Kidney Transplantation | 4 | 2025 | 557 | 0.660 |
Why?
|
| Pruritus | 5 | 2024 | 50 | 0.610 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 79 | 0.610 |
Why?
|
| Adult | 50 | 2025 | 31157 | 0.600 |
Why?
|
| United States | 32 | 2025 | 11883 | 0.600 |
Why?
|
| Drug Resistance, Multiple | 1 | 2019 | 54 | 0.590 |
Why?
|
| Cross-Sectional Studies | 17 | 2024 | 3797 | 0.570 |
Why?
|
| Hypotension | 2 | 2017 | 182 | 0.560 |
Why?
|
| Death | 1 | 2019 | 76 | 0.550 |
Why?
|
| Peritoneal Dialysis | 3 | 2017 | 132 | 0.550 |
Why?
|
| Ultrasonography, Doppler | 1 | 2019 | 185 | 0.540 |
Why?
|
| Methylamines | 2 | 2023 | 21 | 0.540 |
Why?
|
| Dialysis Solutions | 4 | 2020 | 17 | 0.540 |
Why?
|
| Serum Albumin | 3 | 2017 | 101 | 0.530 |
Why?
|
| Patient Education as Topic | 1 | 2021 | 461 | 0.530 |
Why?
|
| Hemodialysis, Home | 1 | 2017 | 13 | 0.520 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2017 | 41 | 0.520 |
Why?
|
| Venous Pressure | 1 | 2016 | 11 | 0.490 |
Why?
|
| Vena Cava, Inferior | 1 | 2016 | 93 | 0.460 |
Why?
|
| Arginine | 2 | 2023 | 337 | 0.460 |
Why?
|
| Atherosclerosis | 8 | 2023 | 947 | 0.450 |
Why?
|
| Nutrition Surveys | 2 | 2019 | 328 | 0.450 |
Why?
|
| Hospitalization | 5 | 2018 | 1939 | 0.440 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 916 | 0.430 |
Why?
|
| Fructosamine | 2 | 2017 | 10 | 0.420 |
Why?
|
| Systole | 2 | 2014 | 195 | 0.410 |
Why?
|
| Iron | 4 | 2021 | 305 | 0.400 |
Why?
|
| Health Equity | 2 | 2025 | 77 | 0.400 |
Why?
|
| Vascular Calcification | 3 | 2022 | 69 | 0.400 |
Why?
|
| Precision Medicine | 1 | 2017 | 385 | 0.390 |
Why?
|
| Cause of Death | 7 | 2019 | 502 | 0.380 |
Why?
|
| Arteriovenous Shunt, Surgical | 3 | 2019 | 86 | 0.380 |
Why?
|
| Healthcare Disparities | 3 | 2025 | 514 | 0.370 |
Why?
|
| beta 2-Microglobulin | 4 | 2017 | 35 | 0.370 |
Why?
|
| Hypokalemia | 2 | 2011 | 41 | 0.370 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 508 | 0.360 |
Why?
|
| Focus Groups | 2 | 2025 | 232 | 0.360 |
Why?
|
| Uremia | 3 | 2024 | 33 | 0.360 |
Why?
|
| Diabetes Mellitus | 5 | 2023 | 891 | 0.350 |
Why?
|
| Blood Volume | 3 | 2016 | 73 | 0.340 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 3 | 2026 | 44 | 0.340 |
Why?
|
| Patient-Centered Care | 3 | 2025 | 231 | 0.340 |
Why?
|
| Follow-Up Studies | 13 | 2019 | 5164 | 0.330 |
Why?
|
| Polyomavirus Infections | 1 | 2011 | 87 | 0.330 |
Why?
|
| Proteinuria | 3 | 2021 | 108 | 0.320 |
Why?
|
| Proportional Hazards Models | 8 | 2019 | 1391 | 0.320 |
Why?
|
| Pain | 2 | 2022 | 429 | 0.300 |
Why?
|
| Predictive Value of Tests | 9 | 2020 | 2294 | 0.290 |
Why?
|
| Health Services Accessibility | 2 | 2025 | 697 | 0.290 |
Why?
|
| Chlorthalidone | 1 | 2008 | 25 | 0.290 |
Why?
|
| Atrial Fibrillation | 3 | 2021 | 737 | 0.290 |
Why?
|
| Hippurates | 3 | 2017 | 7 | 0.280 |
Why?
|
| Prognosis | 9 | 2021 | 4867 | 0.270 |
Why?
|
| Renal Insufficiency | 2 | 2023 | 257 | 0.270 |
Why?
|
| Incidence | 8 | 2023 | 3320 | 0.270 |
Why?
|
| Graft Rejection | 1 | 2011 | 556 | 0.260 |
Why?
|
| Immunosuppressive Agents | 1 | 2011 | 655 | 0.260 |
Why?
|
| Mortality | 5 | 2018 | 261 | 0.250 |
Why?
|
| Time Factors | 11 | 2024 | 6215 | 0.250 |
Why?
|
| Fatigue | 3 | 2024 | 192 | 0.250 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2025 | 214 | 0.250 |
Why?
|
| Feeding Behavior | 1 | 2012 | 708 | 0.250 |
Why?
|
| Potassium | 4 | 2013 | 265 | 0.240 |
Why?
|
| Naphthyridines | 1 | 2026 | 12 | 0.240 |
Why?
|
| Paresthesia | 2 | 2024 | 9 | 0.230 |
Why?
|
| Antiviral Agents | 1 | 2011 | 801 | 0.230 |
Why?
|
| Prevalence | 5 | 2020 | 2688 | 0.230 |
Why?
|
| Goat Diseases | 1 | 2025 | 2 | 0.220 |
Why?
|
| Morbidity | 2 | 2017 | 257 | 0.220 |
Why?
|
| Orf virus | 1 | 2025 | 5 | 0.220 |
Why?
|
| Ecthyma, Contagious | 1 | 2025 | 6 | 0.220 |
Why?
|
| Fellowships and Scholarships | 2 | 2019 | 323 | 0.220 |
Why?
|
| Glutamine | 2 | 2017 | 201 | 0.220 |
Why?
|
| Retrospective Studies | 13 | 2024 | 17557 | 0.220 |
Why?
|
| Acute Kidney Injury | 3 | 2019 | 700 | 0.220 |
Why?
|
| Longitudinal Studies | 6 | 2021 | 1486 | 0.210 |
Why?
|
| Models, Biological | 3 | 2024 | 1383 | 0.210 |
Why?
|
| Proteomics | 2 | 2025 | 616 | 0.210 |
Why?
|
| Hypertension, Malignant | 1 | 2004 | 7 | 0.210 |
Why?
|
| Hand Strength | 1 | 2024 | 56 | 0.210 |
Why?
|
| Hyperoxaluria | 1 | 2023 | 6 | 0.210 |
Why?
|
| Trust | 1 | 2025 | 88 | 0.200 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2017 | 216 | 0.200 |
Why?
|
| Survival Rate | 9 | 2024 | 2114 | 0.200 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2023 | 17 | 0.200 |
Why?
|
| Oxalates | 2 | 2023 | 22 | 0.200 |
Why?
|
| Treatment Outcome | 15 | 2026 | 12865 | 0.190 |
Why?
|
| Comorbidity | 6 | 2017 | 1583 | 0.190 |
Why?
|
| Serotonin Syndrome | 1 | 2002 | 1 | 0.190 |
Why?
|
| Meperidine | 1 | 2002 | 5 | 0.190 |
Why?
|
| Cyclohexanols | 1 | 2002 | 9 | 0.190 |
Why?
|
| Amitriptyline | 1 | 2002 | 27 | 0.190 |
Why?
|
| Surveys and Questionnaires | 5 | 2021 | 4034 | 0.190 |
Why?
|
| Hospitalists | 1 | 2003 | 53 | 0.190 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2020 | 774 | 0.190 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2002 | 42 | 0.180 |
Why?
|
| Aged, 80 and over | 11 | 2019 | 6800 | 0.180 |
Why?
|
| Resilience, Psychological | 1 | 2023 | 80 | 0.180 |
Why?
|
| Analgesics | 1 | 2002 | 119 | 0.170 |
Why?
|
| Coronary Artery Disease | 2 | 2022 | 893 | 0.170 |
Why?
|
| Anemia | 2 | 2017 | 352 | 0.170 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2002 | 149 | 0.170 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2022 | 130 | 0.170 |
Why?
|
| Symptom Assessment | 2 | 2021 | 109 | 0.170 |
Why?
|
| Renin | 1 | 2021 | 75 | 0.170 |
Why?
|
| Contrast Media | 1 | 2024 | 474 | 0.170 |
Why?
|
| Machine Learning | 1 | 2025 | 381 | 0.170 |
Why?
|
| Abdominal Fat | 1 | 2020 | 22 | 0.160 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2021 | 80 | 0.160 |
Why?
|
| Incretins | 1 | 2020 | 26 | 0.160 |
Why?
|
| Body Surface Area | 1 | 2020 | 37 | 0.160 |
Why?
|
| Drug Approval | 1 | 2020 | 46 | 0.160 |
Why?
|
| Patients | 1 | 2021 | 123 | 0.160 |
Why?
|
| Bayes Theorem | 1 | 2021 | 308 | 0.160 |
Why?
|
| Blood Glucose | 2 | 2022 | 1109 | 0.160 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2020 | 22 | 0.160 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2023 | 109 | 0.160 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 154 | 0.150 |
Why?
|
| Minerals | 1 | 2019 | 58 | 0.150 |
Why?
|
| Ketone Bodies | 1 | 2019 | 41 | 0.150 |
Why?
|
| Waiting Lists | 1 | 2021 | 245 | 0.150 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 42 | 0.150 |
Why?
|
| Blood Pressure Determination | 2 | 2014 | 119 | 0.150 |
Why?
|
| Immunologic Factors | 1 | 2020 | 190 | 0.140 |
Why?
|
| Caregivers | 1 | 2025 | 577 | 0.140 |
Why?
|
| Frailty | 1 | 2021 | 140 | 0.140 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 320 | 0.140 |
Why?
|
| Vascular Grafting | 1 | 2018 | 51 | 0.140 |
Why?
|
| Body Size | 1 | 2018 | 60 | 0.140 |
Why?
|
| Hematuria | 1 | 2018 | 48 | 0.140 |
Why?
|
| Reproducibility of Results | 4 | 2022 | 2901 | 0.140 |
Why?
|
| ROC Curve | 2 | 2020 | 611 | 0.140 |
Why?
|
| Algorithms | 3 | 2021 | 1665 | 0.140 |
Why?
|
| Pulmonary Edema | 1 | 2018 | 54 | 0.140 |
Why?
|
| Cluster Analysis | 1 | 2019 | 412 | 0.140 |
Why?
|
| Diabetes Complications | 3 | 2019 | 197 | 0.140 |
Why?
|
| Family | 1 | 2021 | 586 | 0.130 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2017 | 31 | 0.130 |
Why?
|
| Glucose | 1 | 2022 | 851 | 0.130 |
Why?
|
| Hepatitis B, Chronic | 1 | 2018 | 83 | 0.130 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2018 | 78 | 0.130 |
Why?
|
| Angiotensin II Type 2 Receptor Blockers | 1 | 2017 | 5 | 0.130 |
Why?
|
| Glycation End Products, Advanced | 2 | 2017 | 26 | 0.130 |
Why?
|
| Glomerulonephritis | 1 | 2017 | 75 | 0.130 |
Why?
|
| Trace Elements | 1 | 2017 | 21 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2021 | 1447 | 0.120 |
Why?
|
| Oliguria | 1 | 2016 | 20 | 0.120 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2016 | 23 | 0.120 |
Why?
|
| Netherlands | 1 | 2016 | 50 | 0.120 |
Why?
|
| Baltimore | 1 | 2016 | 45 | 0.120 |
Why?
|
| Prostheses and Implants | 1 | 2017 | 147 | 0.120 |
Why?
|
| Weight Gain | 2 | 2015 | 383 | 0.120 |
Why?
|
| Defibrillators, Implantable | 1 | 2018 | 214 | 0.120 |
Why?
|
| Hyperglycemia | 1 | 2017 | 233 | 0.120 |
Why?
|
| Body Composition | 1 | 2018 | 543 | 0.110 |
Why?
|
| Pleural Effusion | 1 | 2016 | 103 | 0.110 |
Why?
|
| Linear Models | 2 | 2020 | 686 | 0.110 |
Why?
|
| Renal Replacement Therapy | 1 | 2017 | 165 | 0.110 |
Why?
|
| Insulin Resistance | 1 | 2020 | 687 | 0.110 |
Why?
|
| Phosphorus | 1 | 2015 | 60 | 0.110 |
Why?
|
| Area Under Curve | 1 | 2016 | 303 | 0.110 |
Why?
|
| Dyspnea | 1 | 2016 | 159 | 0.110 |
Why?
|
| Cardiotonic Agents | 1 | 2016 | 141 | 0.110 |
Why?
|
| Iron Compounds | 1 | 2014 | 2 | 0.110 |
Why?
|
| Metabolome | 1 | 2017 | 325 | 0.110 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 3031 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 89 | 0.110 |
Why?
|
| Chi-Square Distribution | 2 | 2014 | 564 | 0.110 |
Why?
|
| Young Adult | 9 | 2021 | 10015 | 0.110 |
Why?
|
| Patient Readmission | 1 | 2018 | 435 | 0.110 |
Why?
|
| Vascular Stiffness | 1 | 2015 | 81 | 0.110 |
Why?
|
| Sex Factors | 4 | 2021 | 1340 | 0.110 |
Why?
|
| Body Weight | 2 | 2015 | 986 | 0.110 |
Why?
|
| Logistic Models | 1 | 2019 | 1793 | 0.110 |
Why?
|
| Osteoprotegerin | 1 | 2014 | 9 | 0.100 |
Why?
|
| alpha-2-HS-Glycoprotein | 1 | 2014 | 8 | 0.100 |
Why?
|
| Fibroblast Growth Factors | 1 | 2015 | 171 | 0.100 |
Why?
|
| Early Medical Intervention | 1 | 2014 | 32 | 0.100 |
Why?
|
| Albuminuria | 2 | 2026 | 105 | 0.100 |
Why?
|
| Cognitive Dysfunction | 1 | 2018 | 337 | 0.100 |
Why?
|
| Prescriptions | 1 | 2013 | 44 | 0.100 |
Why?
|
| Curriculum | 1 | 2019 | 792 | 0.100 |
Why?
|
| Incidental Findings | 1 | 2014 | 122 | 0.100 |
Why?
|
| Ultrasonography | 1 | 2018 | 946 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 228 | 0.100 |
Why?
|
| Choice Behavior | 1 | 2014 | 140 | 0.100 |
Why?
|
| Catheterization, Central Venous | 1 | 2014 | 137 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 337 | 0.100 |
Why?
|
| Inflammation | 1 | 2020 | 1485 | 0.090 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2018 | 401 | 0.090 |
Why?
|
| Causality | 3 | 2021 | 90 | 0.090 |
Why?
|
| Sepsis | 1 | 2017 | 496 | 0.090 |
Why?
|
| Exercise | 1 | 2018 | 862 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2018 | 558 | 0.090 |
Why?
|
| Registries | 3 | 2014 | 1614 | 0.090 |
Why?
|
| Ventricular Function, Left | 1 | 2015 | 546 | 0.090 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2023 | 134 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2025 | 1272 | 0.080 |
Why?
|
| Potassium, Dietary | 1 | 2010 | 13 | 0.080 |
Why?
|
| Residence Characteristics | 1 | 2013 | 293 | 0.080 |
Why?
|
| Heart Ventricles | 1 | 2015 | 759 | 0.080 |
Why?
|
| Administration, Intravenous | 3 | 2017 | 170 | 0.080 |
Why?
|
| Urine | 1 | 2010 | 89 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 1610 | 0.080 |
Why?
|
| Parathyroid Hormone | 2 | 2023 | 83 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2012 | 826 | 0.080 |
Why?
|
| Erythropoietin | 1 | 2010 | 102 | 0.080 |
Why?
|
| Reserpine | 1 | 2008 | 8 | 0.070 |
Why?
|
| Clinical Decision-Making | 2 | 2025 | 311 | 0.070 |
Why?
|
| Atenolol | 1 | 2008 | 43 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2020 | 2085 | 0.070 |
Why?
|
| Vitamin D | 2 | 2023 | 196 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2011 | 278 | 0.070 |
Why?
|
| Quality Improvement | 1 | 2012 | 707 | 0.060 |
Why?
|
| Electronic Health Records | 2 | 2025 | 821 | 0.060 |
Why?
|
| North Carolina | 1 | 2025 | 40 | 0.060 |
Why?
|
| Mississippi | 1 | 2025 | 35 | 0.060 |
Why?
|
| Pennsylvania | 1 | 2025 | 60 | 0.060 |
Why?
|
| Veterans | 1 | 2017 | 1753 | 0.060 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2025 | 36 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 1167 | 0.060 |
Why?
|
| Goats | 1 | 2025 | 30 | 0.060 |
Why?
|
| Comparative Effectiveness Research | 1 | 2025 | 72 | 0.050 |
Why?
|
| Coronary Disease | 2 | 2012 | 627 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2021 | 1071 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 1 | 2024 | 127 | 0.050 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2004 | 6 | 0.050 |
Why?
|
| India | 1 | 2025 | 232 | 0.050 |
Why?
|
| Walking Speed | 1 | 2024 | 18 | 0.050 |
Why?
|
| Angiotensins | 1 | 2023 | 9 | 0.050 |
Why?
|
| Sterols | 1 | 2023 | 16 | 0.050 |
Why?
|
| Nausea | 1 | 2024 | 83 | 0.050 |
Why?
|
| Life Expectancy | 1 | 2024 | 63 | 0.050 |
Why?
|
| Naphthalenes | 1 | 2023 | 37 | 0.050 |
Why?
|
| Oligonucleotides | 1 | 2023 | 94 | 0.050 |
Why?
|
| Europe | 1 | 2024 | 364 | 0.050 |
Why?
|
| Pituitary-Adrenal System | 1 | 2023 | 33 | 0.050 |
Why?
|
| DNA, Viral | 1 | 2025 | 452 | 0.050 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2023 | 57 | 0.050 |
Why?
|
| Gait | 1 | 2024 | 141 | 0.050 |
Why?
|
| Aging | 2 | 2023 | 1244 | 0.050 |
Why?
|
| Vitamins | 1 | 2023 | 112 | 0.050 |
Why?
|
| Employment | 1 | 2023 | 71 | 0.050 |
Why?
|
| Venlafaxine Hydrochloride | 1 | 2002 | 20 | 0.050 |
Why?
|
| Emergencies | 1 | 2004 | 176 | 0.050 |
Why?
|
| Phylogeny | 1 | 2025 | 687 | 0.050 |
Why?
|
| Japan | 1 | 2023 | 161 | 0.050 |
Why?
|
| Fluconazole | 1 | 2002 | 48 | 0.050 |
Why?
|
| Deoxycholic Acid | 1 | 2022 | 14 | 0.050 |
Why?
|
| Hospital Costs | 1 | 2003 | 184 | 0.050 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2003 | 163 | 0.050 |
Why?
|
| Walking | 1 | 2024 | 227 | 0.040 |
Why?
|
| Methadone | 1 | 2002 | 127 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2002 | 238 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2003 | 182 | 0.040 |
Why?
|
| Myalgia | 1 | 2021 | 9 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2025 | 1456 | 0.040 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2002 | 125 | 0.040 |
Why?
|
| Ichthyosis | 1 | 2021 | 31 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2022 | 137 | 0.040 |
Why?
|
| Brain Ischemia | 1 | 2004 | 268 | 0.040 |
Why?
|
| Age Factors | 2 | 2018 | 2830 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2021 | 89 | 0.040 |
Why?
|
| Unsupervised Machine Learning | 1 | 2021 | 12 | 0.040 |
Why?
|
| Heart Function Tests | 1 | 2021 | 50 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2025 | 559 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2002 | 227 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2023 | 535 | 0.040 |
Why?
|
| Graft Survival | 2 | 2018 | 459 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2002 | 327 | 0.040 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2020 | 46 | 0.040 |
Why?
|
| Coronary Angiography | 1 | 2003 | 453 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2003 | 408 | 0.040 |
Why?
|
| Renal Elimination | 1 | 2020 | 11 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2021 | 332 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2020 | 1679 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 448 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2002 | 290 | 0.040 |
Why?
|
| Blood Urea Nitrogen | 1 | 2020 | 69 | 0.040 |
Why?
|
| Sodium | 1 | 2021 | 278 | 0.040 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2020 | 74 | 0.040 |
Why?
|
| Prealbumin | 1 | 2019 | 27 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2020 | 163 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2014 | 1231 | 0.040 |
Why?
|
| China | 1 | 2020 | 277 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2025 | 707 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2018 | 44 | 0.040 |
Why?
|
| Decision Making | 1 | 2004 | 711 | 0.030 |
Why?
|
| Bone Density | 1 | 2021 | 364 | 0.030 |
Why?
|
| Vascular Patency | 1 | 2018 | 179 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2019 | 232 | 0.030 |
Why?
|
| Independent Living | 1 | 2018 | 65 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 2022 | 525 | 0.030 |
Why?
|
| Palmitic Acids | 1 | 2017 | 5 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2002 | 1240 | 0.030 |
Why?
|
| Kynurenic Acid | 1 | 2017 | 9 | 0.030 |
Why?
|
| Guanosine | 1 | 2017 | 12 | 0.030 |
Why?
|
| Homovanillic Acid | 1 | 2017 | 30 | 0.030 |
Why?
|
| Length of Stay | 1 | 2003 | 1404 | 0.030 |
Why?
|
| Deoxyglucose | 1 | 2017 | 41 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 183 | 0.030 |
Why?
|
| Quality Control | 1 | 2017 | 115 | 0.030 |
Why?
|
| Community Health Services | 1 | 2017 | 86 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2017 | 102 | 0.030 |
Why?
|
| Hemodialysis Solutions | 1 | 2016 | 7 | 0.030 |
Why?
|
| Fasting | 1 | 2017 | 304 | 0.030 |
Why?
|
| Health Status | 1 | 2018 | 371 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2017 | 298 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 2017 | 146 | 0.030 |
Why?
|
| Citrulline | 1 | 2017 | 123 | 0.030 |
Why?
|
| Lipids | 1 | 2019 | 560 | 0.030 |
Why?
|
| Valsalva Maneuver | 1 | 2015 | 8 | 0.030 |
Why?
|
| Photoplethysmography | 1 | 2015 | 11 | 0.030 |
Why?
|
| Iothalamic Acid | 1 | 2015 | 4 | 0.030 |
Why?
|
| Stroke | 1 | 2004 | 1060 | 0.030 |
Why?
|
| Patient Admission | 1 | 2017 | 186 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2017 | 286 | 0.030 |
Why?
|
| Pulse Wave Analysis | 1 | 2015 | 52 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 2015 | 94 | 0.030 |
Why?
|
| Fingers | 1 | 2015 | 63 | 0.030 |
Why?
|
| Hemostasis | 1 | 2015 | 76 | 0.030 |
Why?
|
| Kinetics | 1 | 2017 | 1083 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 320 | 0.030 |
Why?
|
| Obesity | 2 | 2004 | 2384 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2012 | 1484 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2003 | 876 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 221 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2017 | 237 | 0.030 |
Why?
|
| Organ Size | 1 | 2015 | 410 | 0.030 |
Why?
|
| Maryland | 1 | 2014 | 39 | 0.030 |
Why?
|
| Ferritins | 1 | 2014 | 105 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 746 | 0.030 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2014 | 26 | 0.030 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2014 | 29 | 0.030 |
Why?
|
| Patient Care | 1 | 2014 | 98 | 0.030 |
Why?
|
| Institutionalization | 1 | 2013 | 13 | 0.030 |
Why?
|
| Osteopontin | 1 | 2014 | 54 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2014 | 242 | 0.020 |
Why?
|
| Vital Capacity | 1 | 2013 | 81 | 0.020 |
Why?
|
| Cognition | 1 | 2018 | 817 | 0.020 |
Why?
|
| Nursing Homes | 1 | 2013 | 88 | 0.020 |
Why?
|
| Disease Management | 1 | 2017 | 555 | 0.020 |
Why?
|
| Adolescent | 3 | 2018 | 20774 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2012 | 237 | 0.020 |
Why?
|
| Hyperkalemia | 1 | 2013 | 69 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 760 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1375 | 0.020 |
Why?
|
| Calcium | 1 | 2015 | 1020 | 0.020 |
Why?
|
| Echocardiography | 1 | 2015 | 1131 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 1216 | 0.020 |
Why?
|
| Pregnancy | 1 | 2021 | 7403 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2063 | 0.010 |
Why?
|
| Insulin | 1 | 2010 | 1140 | 0.010 |
Why?
|
| Diastole | 1 | 2004 | 181 | 0.010 |
Why?
|
| Animals | 1 | 2025 | 33856 | 0.010 |
Why?
|
| Radial Artery | 1 | 2003 | 33 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2002 | 667 | 0.010 |
Why?
|
| Recurrence | 1 | 2002 | 1478 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2004 | 1542 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2002 | 688 | 0.010 |
Why?
|